Litcius/Paper detail

SARS‐CoV‐2 and hypertension

Briyanth Ravichandran, Daniela Grimm, Marcus Krüger, Sascha Kopp, Manfred Infanger, Markus Wehland

2021Physiological Reports27 citationsDOIOpen Access PDF

Abstract

R and ACE2/ANG-(1-7)/MAS. The main regulatory protein in balancing the RAAS is angiotensin-converting enzyme 2 (ACE2). The protein also functions as the main mediator of endocytosis of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the host cell. SARS-CoV-2 is the cause of COVID-19 and has caused a worldwide pandemic; however, the treatment and prophylaxis of COVID-19 are limited. Several drugs and vaccines are currently being tested in clinical trials with a few already approved by EMA and FDA. HT is a major risk factor regarding the severity and fatality of COVID-19, and the RAAS plays an important role in COVID-19 infection since SARS-CoV-2 can lead to a dysregulation of the system by reducing the ACE2 expression. The exact mechanisms of HT in relation to COVID-19 remain uncertain, and more research is needed for further elucidation.

Topics & Concepts

MedicineDiseaseCase fatality rateRenin–angiotensin systemIntensive care medicineClinical trialCoronavirus disease 2019 (COVID-19)PandemicCoronavirusBlood pressureBioinformaticsInternal medicineImmunologyInfectious disease (medical specialty)EpidemiologyBiologyCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19